1-3 of 3
Mari Gilljam
Close
Sort by
Journal Articles

CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion

Hareth Nahi, Michael Chrobook, Stephan Meinke, Charlotte Gran, Nicole Marquardt, Gabriel Afram, Tolga Sutlu, Mari Gilljam, Birgitta Stellan, Arnika Kathleen Wagner, Lilian Walther-Jallow, Johan Liwing, Monika Klimkowska, Goesta Gahrton, Per Ljungman, Hans-Gustaf Ljunggren, Evren Alici
Journal: Blood
Blood (2021) 138 (Supplement 1): 4796.
https://doi.org/10.1182/blood-2021-152522
Published: 2021
Journal Articles

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

Maria Karvouni, MSc, PharmD, Heyue Zhou, Arnika Kathleen Wagner, PhD, Qiangzhong Ma, Alamdar H. Baloch, PhD, Tong Zhu, Hong Zhang, Mari Gilljam, Andreas Lundqvist, PhD, Gunnar F. Kaufmann, PhD, Evren Alici, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1848.
https://doi.org/10.1182/blood-2019-127893
Published: 2019
Journal Articles

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

Evren Alici, Tolga Sutlu, Bo Björkstrand, Mari Gilljam, Birgitta Stellan, Hareth Nahi, Hernan Concha Quezada, Gösta Gahrton, Hans-Gustaf Ljunggren, M. Sirac Dilber
Journal: Blood
Blood (2008) 111 (6): 3155–3162.
https://doi.org/10.1182/blood-2007-09-110312
Published: 2008
Includes: Supplemental data